Beta Bionics iLet Bionic Pancreas

The iLet Bionic Pancreas is a tubed, rechargeable insulin pump whose defining feature is its software, not its hardware: it is the first system designed to be set up with only your body weight — no basal rates, no insulin-to-carb ratios, and no correction factors.¹ Because the dosing logic is so different from every other pump, the iLet is best understood and ranked as its own delivery device.

Form factor & wear. It is a durable, tubed pump (not a patch), weighing about 110 g with a full cartridge, with a colour touchscreen and an IPX8 water-resistance rating (immersion to ~12 feet for 30 minutes).² Insulin sits in an ~180-unit fillable glass cartridge, or you can use a 160-unit (1.6 mL) prefilled Fiasp cartridge.²¹ It connects to the body through a standard tubed infusion set; only 6 mm cannulas are offered, in a Teflon set worn up to 3 days or a steel set worn up to 2 days.¹

Reliability & occlusion detection. A dedicated occlusion alarm suspends insulin when flow is blocked and must be acknowledged before dosing resumes, alongside low-insulin and "insulin out" alarms.¹ In the pivotal trial, infusion-set failures occurred at roughly 1.3% per day — essentially the same rate as the well-established Tandem Control-IQ pump.¹ The control algorithm runs every 5 minutes and will fully suspend basal insulin for low or rapidly falling glucose.¹

Which CGMs, algorithms & DIY it works with. The iLet pairs with Dexcom G6, Dexcom G7, and the Abbott FreeStyle Libre 3 Plus; the Dexcom sensors can be calibrated from the pump, the Libre cannot.¹³ Crucially, it is a closed ecosystem: it always runs only its own FDA-cleared dosing software and cannot be used with DIY/open-source systems or any third-party algorithm.⁴¹ It is cleared for rapid-acting U-100 insulin only — Humalog (lispro), NovoLog (aspart), and Fiasp.¹

How dosing works. Three algorithms run in parallel — an adaptive basal algorithm, a model-predictive-control bolus algorithm, and a separate meal-dose algorithm — and they adapt continuously to your needs.¹ Instead of counting carbs, you announce a meal as "usual for me," "more," or "less," separately for breakfast, lunch, and dinner.¹ The only adjustable setting is a glucose target ("Usual" 120, "Lower" 110, or "Higher" 130 mg/dL).¹

Phone bolusing. There is none. The companion smartphone app is view-only — it mirrors glucose, trend, and alerts — and every meal announcement or dose is entered on the pump's own touchscreen.⁵

Evidence. Across multicentre randomised trials in adults and in youth 6–17, the iLet lowered HbA1c by about 0.5% and raised time-in-range by roughly 2.4–3.4 hours per day versus standard care, without increasing hypoglycaemia, with the largest gains in people starting at high HbA1c.⁶⁷⁸ It also improved control in cystic-fibrosis-related diabetes.⁹

Real-world data, published openly. In June 2026 Beta Bionics became the first automated-insulin-delivery company to publish near-real-time real-world outcomes on a public website, covering 100% of iLet patients who meet two pre-stated criteria — a provider-reported baseline HbA1c, and at least two weeks of uploaded CGM data — with no exclusions applied.¹⁰¹¹ Alongside it, three years of post-market data (19 May 2023 – 19 May 2026), discussed at ADA 2026, show time in range improving by 25% in that group.¹² Read that number carefully: it is a within-cohort change among users who upload their data and had a baseline on file — a self-selected group — not a head-to-head comparison against another system, and no baseline value is given, so whether "25%" is a relative or an absolute change is not stated. The genuinely notable part is the method: publishing everyone who qualifies, live, with nobody filtered out, is a higher bar than any other pump maker currently meets.

Access & cost (US). The iLet is FDA-cleared and US-only.⁴ It is covered under commercial, Medicare and Medicaid plans, and major pharmacy-benefit managers (Express Scripts, Prime Therapeutics) have added it to national formularies, which can sharply reduce the up-front pump cost.¹³

What's coming. Beta Bionics is developing "Bionic Circle," a companion app intended to add remote monitoring/sharing, and continues to expand CGM compatibility (Libre 3 Plus support was a recent addition).¹⁴

The bigger hardware change is Mint, the company's first tubeless patch pump, designed to pair with the dosing algorithm the iLet already runs. Mint is not cleared. Its 510(k) — as an alternate-controller-enabled (ACE) insulin pump — is under FDA review. In May 2026 Beta Bionics brought its expectation forward, to full commercialisation by the end of Q2 2027, citing the FDA's initial responses to that application and progress scaling Mint manufacturing.¹⁵ That is a company target subject to clearance, not an approval date — treat it as such.

The longer-term roadmap returns to the project's origin: a bihormonal version that doses both insulin and glucagon, which the iLet hardware was originally designed to support.⁹

References

1. Beta Bionics. iLet Bionic Pancreas System: Guide for Health Care Providers (LA000079_F). Beta Bionics (2025). https://www.betabionics.com/wp-content/uploads/LA000079_F-iLet-Bionic-Pancreas-System-HCP-Guide-Clean-r2.pdf ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

2. American Diabetes Association. iLet Bionic Pancreas System — Consumer Guide. ADA Consumer Guide (2024). https://consumerguide.diabetes.org/products/insulin-pumps/ilet-bionic-pancreas-system ↩ ↩²

3. Dexcom. iLet (Beta Bionics) and Dexcom G7 FAQs. Dexcom (2024). https://www.dexcom.com/en-us/faqs/ilet-beta-bionics-dexcom-g7-faqs ↩

4. U.S. FDA. iLet ACE Pump and iLet Dosing Decision Software — 510(k) K223846 Summary. FDA (2023). https://www.accessdata.fda.gov/cdrh_docs/pdf22/K223846.pdf ↩ ↩²

5. Beta Bionics. Compatibility for iLet and Bionic Circle Apps. Beta Bionics Support (2025). https://www.betabionics.com/support/compatibility/ ↩

6. Kruger D, et al. A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9634987/ ↩

7. Messer LH, et al. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6–17 Years Old with Type 1 Diabetes. Diabetes Technol Ther (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9529304/ ↩

8. Beck RW, et al. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9529301/ ↩

9. Sherwood JS, et al. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis-Related Diabetes. Diabetes Care (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC10733649/ ↩ ↩²

10. Beta Bionics. Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website (Jun 2, 2026; covers 100% of iLet patients meeting two pre-stated criteria, with no exclusions applied). GlobeNewswire (2026). https://www.globenewswire.com/news-release/2026/06/02/3305268/0/en/beta-bionics-first-in-automated-insulin-delivery-to-publish-near-real-time-real-world-data-on-a-public-website.html ↩

11. Beta Bionics. Real-World Data on the iLet, shown in real time. Beta Bionics (2026). https://www.betabionics.com/hcp/real-world-data/ ↩

12. Drug Delivery Business News. Beta Bionics real-world data shows 25% time in range improvement with iLet (post-market surveillance from May 19, 2023 to May 19, 2026; users with a baseline value on file who uploaded at least two weeks of CGM data; discussed at ADA 2026). Drug Delivery Business News (2026). https://www.drugdeliverybusiness.com/beta-bionics-real-world-data-shows-25-time-in-range-improvement-with-ilet/ ↩

13. Hibbs N. Beta Bionics earns pharmacy benefit win for bionic pancreas. Drug Delivery Business News (2025). https://www.drugdeliverybusiness.com/beta-bionics-pharmacy-benefit-bionic-pancreas/ ↩

14. Beta Bionics. Compatibility & supported devices. Beta Bionics Support (2025). https://www.betabionics.com/support/compatibility/ ↩

15. Beta Bionics. Beta Bionics Updates Commercialization Timeline Expectations for Mint, its Patch Pump in Development (May 21, 2026; expectation moved forward to full commercialisation by end of Q2 2027, subject to FDA clearance, based on the FDA's initial responses to the Mint ACE-pump 510(k) and manufacturing scale-up). Beta Bionics Investor Relations (2026). https://investors.betabionics.com/news-releases/news-release-details/beta-bionics-updates-commercialization-timeline-expectations ↩